V. Menon

发表

CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women

Jeffrey R. Wilson, R. Collins, G. Swingler, 1994, The Lancet.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

J. Kastelein, J. Jukema, W. Koenig, 2014, JAMA.

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.

D. Mozaffarian, P. Ridker, P. Barter, 2020, JAMA.

Long-Term Cardiovascular Outcomes After Bariatric Surgery in the Medicare Population.

M. Desai, A. Pandey, A. Aminian, 2022, Journal of the American College of Cardiology.

Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial).

T. Lüscher, A. Lincoff, S. Nissen, 2019, The American journal of cardiology.

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.

P. Libby, D. Solomon, A. Lincoff, 2017, The American journal of medicine.

Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.

J. S. St. John, A. Lincoff, S. Nissen, 2020, JAMA cardiology.

The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE

A. Lincoff, S. Nissen, E. McErlean, 2019, Diabetes Care.

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial.

D. Mozaffarian, P. Ridker, J. Kastelein, 2021, JAMA cardiology.

ALOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES AFTER ACUTE CORONARY SYNDROMES: HEART FAILURE OUTCOMES AND CARDIOVASCULAR SAFETY IN HEART FAILURE PATIENTS

W. Cushman, C. Cannon, G. Bakris, 2014 .

Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease.

A. Lincoff, S. Nissen, S. Nicholls, 2021, The American journal of cardiology.

Is the Combination of Aspirin and Clopidogrel always Better than Aspirin Alone? Or will it be too much of a good thing?

V. Menon, 2008, Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia.

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

P. Libby, D. Graham, F. Ruschitzka, 2016, The New England journal of medicine.

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

A. Lincoff, S. Nissen, E. McErlean, 2019, Journal of the American Heart Association.

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

J. S. St. John, A. Lincoff, S. Nissen, 2020, BMJ Open Diabetes Research & Care.

Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.

M. Shao, B. Williams, G. Bakris, 2015, Atherosclerosis.

Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus

A. Lincoff, V. Menon, A. Lincoff, 2014, Circulation.

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.

D. Grobbee, P. Thompson, J. Kastelein, 2023, The New England journal of medicine.

Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis

P. Libby, D. Graham, T. Lüscher, 2018, Arthritis & Rheumatology.

Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial

S. Kashyap, A. Lincoff, S. Nissen, 2019, Diabetes & vascular disease research.

Purpura fulminans manifesting with Staphylococcus aureus endocarditis: a case report

Nishant R. Shah, S. Nissen, Anirudh Kumar, 2019, European heart journal. Case reports.

Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.

P. Libby, D. Graham, M. Shao, 2018, Journal of the American College of Cardiology.

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus

W. White, R. Pratley, V. Menon, 2013, Diabetes, obesity & metabolism.

Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial

P. Libby, D. Graham, H. Krum, 2017, European heart journal.

Abstract 17400: Lipoprotein(a) is a Determinant of Residual Cardiovascular Risk in the Setting of Optimal LDL-C in Statin-Treated Patients With Atherosclerotic Cardiovascular Disease

S. Nissen, E. McErlean, S. Nicholls, 2017 .

Quantification of Vasoactive Medications and the "Pharmaco-Mechanical Continuum" in Cardiogenic Shock.

J. Katz, S. Vallabhajosyula, V. Menon, 2022, Circulation: Heart Failure.

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.

P. Libby, P. Ridker, J. Kastelein, 2023, JAMA.

3911Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE

C. Granger, D. Rader, P. Barter, 2017 .

Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease.

A. Lincoff, S. Nissen, S. Nicholls, 2022, The American journal of cardiology.

Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.

V. Menon, Stephen J. Nicholls, Kausik K. Ray, 2024, JAMA cardiology.